Kiyaros AS 20 Capsule is a combination medication containing Rosuvastatin 20 mg and Aspirin 75 mg, indicated for the management of cardiovascular risk in patients with hyperlipidemia and a history of or risk factors for atherosclerotic cardiovascular disease (ASCVD). Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively reduces low-density lipoprotein cholesterol (LDL-C) and other lipid parameters, thereby slowing the progression of atherosclerosis. Aspirin, an antiplatelet agent, inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A2 production and platelet aggregation, which helps prevent thrombotic events such as myocardial infarction and stroke. Kiyaros AS 20 Capsule is particularly beneficial in secondary prevention of cardiovascular events in patients requiring both lipid-lowering and antiplatelet therapy. The combination enhances patient compliance by reducing pill burden. It should be used under medical supervision, with periodic monitoring of lipid profiles, liver function tests, and platelet counts. Caution is advised in patients with active bleeding, hepatic impairment, or aspirin hypersensitivity. Common side effects may include myalgia, gastrointestinal discomfort, and increased risk of bleeding. This product is contraindicated in pregnancy and lactation. Kiyaros AS 20 Capsule offers an effective therapeutic option for comprehensive cardiovascular risk management.